ECHO Trial (The Evidence for Contraceptive options and HIV Outcomes): A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) Implant, and Copper Intrauterine Devices (IUDs)
This multicentre, open-label, randomised clinical trial will compare the risks of HIV acquisition between women randomised to Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) implant, and copper IUDs. The goal of the study is to answer the public health question of the relative risks (HIV acquisition) and benefits (pregnancy prevention) of three commonly-used, effective contraceptive methods among women who desire contraception. Approximately 7,800 sexually active, HIV-negative women not desiring to become pregnant, aged 16-35 years old, seeking effective contraception, and willing to be randomised to any of the study arms, will be randomly allocated to one of three study arms in a 1:1:1 ratio: DMPA, LNG, implant, copper IUD. This study will be conducted in approximately 12 sites in Eastern and Southern Africa. The study is currently in the planning phase.
The Bill & Melinda Gates Foundation via FHI360, USAID,
ECHO Consortium, Site Investigator Prof J Smit (MatCH Research)
MatCH Research Commercial City and Edendale Research Site
A health sector and community-based participatory approach in a human rights framework, to increase met needs for contraception: The UPTAKE Project
The UPTAKE Project is multi-country complex designed intervention using a community and health care provider participation approach in the provision of family planning and contraceptives. The study objective is to increase met needs for family planning/contraception, through the development, implementation and testing of an intervention involving community and health care provider participation within a human rights framework. The study is being conducted in Kenya, South Africa and Zambia. Formative work has been undertaken to understand perceptions of quality of care and barriers and enablers to accessing family planning methods and services. An intervention package is being developed and refined based on findings from the formative phase, using the theory of change model.
WHO (World Health Organisation)
Prof J Smit (MatCH Research)
MatCH Research (SA), KwaZulu Natal, eThekwini municipality
Zambia – University Teaching Hospital (PI – Theresa Nkole); Kenya – International Centre for Reproductive Health – Kenya (PI – Peter Gichangi)
The Quatro Study: Acceptability study of (placebo) vaginal delivery forms for preventing HIV and unintended pregnancy among young women in Zimbabwe and South Africa
Despite the crucial need, available products to prevent HIV infection and pregnancy, such as male condoms, female condoms, and microbicides, are not under women’s control and are inconsistently used, especially in low resource settings. The purpose of the Quatro study is to assess the acceptability, preferences, user experience and effect on sexual behavior of four different vaginal microbicide or MPT delivery forms, using placebo products in 18-30 year old African women: rapidly disintegrating vaginal insert, intravaginal ring (IVR), film and gel. The study also examines adherence to the dosage forms through objective markers, developed for each dosage form prior to the commencement of the study.
In addition, data collection activities will be designed to inform development of product educational messages tailored for young women in these Sub-Saharan African settings. The study will be conducted in Durban, South Africa and Harare, Zimbabwe.
United States Agency for International Development and The Bill & Melinda Gates Foundation via
CONRAD, Arlington, VA, United States and Women’s Global Health Imperative, RTI International, San Francisco, CA, United States